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A double-blind crossover study was performed on 27 
patients with proved fixed coronary artery disease and 
stable angina pectoris. The study was designed to com•
pare the relative efficacy of two combination therapies, 
nifedipine plus propranolol and isosorbide dinitrate plus 
propranolol, in terms of antianginal response and effect 
on exercise tolerance by evaluation of treadmill testing. 
The combination of nifedipine and propranolol was su•
perior to the combination of isosorbide and propranolol 
in reducing the number of anginal attacks (p = 0.03), 
increasing total exercise time (p < 0.02), increasing ox•
ygen consumption achieved at end of exercise (p < 0.03), 
increasing time to onset of pain (p = 0.003) and in•
creasing oxygen consumption achieved at onset of pain 
(p = 0.003). Analysis of the rate-pressure products sug-
Therapy with combinations of different antianginal medi•
cations has gained increasing favor by optimizing treatment 
for patients with symptomatic angina pectoris. The use of 
adjunctive therapy allows for selective titration of appro•
priate antianginal agents in an effort to individualize treat•
ment to each patient's needs, improve clinical outcome and 
reduce unwanted side effects. In this regard, coadministra•
tion of long-acting nitrate preparations with beta-adreno•
receptor blocking agents has been the most common form 
of combination therapy for patients with angina who either 
are refractory to monotherapy or are unsuitable candidates 
for coronary revascularization surgery (l,2). 
Patients with exertional angina often receive a beta-blocker 
as initial treatment. With the introduction of calcium channel 
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gests that the difference in these results may be explained 
by the greater effect of nifedipine on afterload reduction. 
Although nitroglycerin consumption was reduced from 
baseline levels during combination nifedipine therapy 
(p < 0.001), there was no statistical difference between 
nifedipine combination therapy and isosorbide combi•
nation therapy. 
In conclusion, although both combination therapies 
were superior to propranolol therapy alone, the com•
bination of nifedipine and propranolol was more effec•
tive than the combination of isosorbide and propranolol 
in reducing the incidence of angina and improving ex•
ercise performance. Side effects were experienced at a 
similar frequency during both combination therapies. 
(J Am Coil CardioI1985;6:1395-401) 
blocking agents, new choices exist regarding the selection 
of an adjunctive agent. Although numerous investigations 
have demonstrated improved antianginal effect when nifed•
ipine is added to propranolol (3-8), little information is 
available comparing different combination therapies with 
each other. This randomized double-blind crossover study 
was designed to compare the relative efficacy of two dif•
ferent antianginal combination therapies, propranolol plus 
nifedipine and propranolol plus long-acting nitrates, with 
each other as well as with propranolol alone. 
Methods 
Inclusion criteria. Informed consent was obtained from 
30 patients at the time of study entry. All patients were 
between 35 and 75 years of age and were required to have 
had at least four episodes of angina per week during the 
month before study enrollment despite propranolol therapy. 
Evidence of adequate beta-blockade, defined as the dose 
of propranolol providing a heart rate at rest of less than 60 
beats/min or a peak heart rate of less than 125 beats/min 
on exercise treadmill testing, was required for study entry. 
The diagnosis of coronary artery disease was confirmed in 
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all patients by either coronary arteriography (2: 70% stenosis 
of at least one major coronary artery), a positive exercise 
treadmill test (2: I mm horizontal ST segment depression 
0.08 second beyond the J point) or a history of previous 
myocardial infarction. 
Exclusion criteria. Patients were excluded from study 
entry if they had evidence of symptomatic congestive heart 
failure, arrhythmias refractory to conventional therapy, un•
controlled hypertension or insulin-dependent diabetes mel•
litus. Patients who had had a myocardial infarction within 
the month before enrollment or who had undergone aorto•
coronary bypass surgery within the 6 month period before 
enrollment were excluded from the study. 
Protocol. Of the 30 patients entered, 27 were evaluable. 
One patient's data were excluded because of poor drug 
compliance and unreliable documentation of anginal epi•
sodes. A second patient experienced sudden death before 
study completion while receiving nifedipine-propranolol ad•
junctive therapy. A third patient was withdrawn from the 
study during the baseline period because of insufficient fre•
quency of angina when propranolol was titrated to tolerance. 
Of the remaining 27 patients, 23 were male and 4 female 
with a mean age of 61.2 years (range 45 to 74). Twelve 
patients had a history of previous myocardial infarction; 25 
patients had a positive coronary angiogram. All patients, 
except one, had an exercise tolerance test diagnostic of 
myocardial ischemia before study entry. 
Patients entered into the protocol once an adequate dose 
of propranolol as defined had been established. The median 
dose of propranolol was 120 mg/day (range 60 to 240). This 
dose was maintained at a constant level throughout the study. 
At the end of the first week, an exercise tolerance test was 
performed to neutralize training effect and to ensure that 
adequate beta-receptor blockade had been achieved. All pa•
tients then entered a 2 week single-blind phase during which 
placebo was added to their established dose of propranolol. 
A second exercise test obtained at the end of this placebo•
propranolol period served as the baseline stress test. 
The patients were then randomized into one of the two 
study drug treatment groups, receiving either propranolol 
plus nifedipine (adjunctive nifedipine) or propranolol plus 
isosorbide dinitrate (adjunctive isosorbide) administered or•
ally four times daily in a double-blind, double-dummy fash•
ion. The two treatment phases were identical in structure 
and consisted of 3 weeks of safety titration to the maximally 
tolerated dose of study medication followed by 3 weeks of 
a fixed dose of study drug at the maximal dosage achieved 
during the safety titration period. After a repeat exercise 
tolerance test, performed at the end of the first 6 week 
period, patients were crossed over to the alternate study 
drug treatment regimen in which an identical protocol was 
used. 
Dosage of study medications (Table 1). The average 
daily dose of nifedipine was 77.0 mg/day compared with 
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Table 1. Daily Dose of Study Medications for 27 Patients 
Dose 
(mg/day) Nifedipine Isosorbide 
40 6 7 
80 17 6 
120 4 14 
Average 77.0 90.4 
90.4 mg/day of isosorbide dinitrate. Although only 4 pa•
tients could tolerate the maximal dose of 120 mg/day of 
nifedipine, 14 tolerated the maximal dose of 120 mg/day 
of isosorbide dinitrate. Three patients receiving isosorbide 
required either premature termination of this treatment phase 
or crossover to adjunctive nifedipine therapy because of 
intolerable headaches experienced at even the lowest dose 
of isosorbide (40 mg/day) permitted in the study protocol. 
Efficacy variables selected for evaluation included fre•
quency of angina and nitroglycerin consumption as recorded 
in individual patient diaries. In addition, angina threshold, 
functional capacity, heart rate and blood pressure response 
to exercise were assessed using a modified Balke-Ware pro•
tocol (Table 2). The efficacy of the two adjunctive treatment 
regimens was analyzed during the final week of each of the 
fixed dose periods (that is, study weeks 9 and IS). Patients 
unable to tolerate adjunctive isosorbide were exercised be•
fore crossover to nifedipine or termination of isosorbide 
therapy. Statistical analyses included an analysis of variance 
for crossover design. 
Results 
A summary of the individual data points for all patients 
showing frequency of anginal attacks, number of nitro•
glycerin tablets consumed and total exercise duration during 
the three phases of the trial is presented in Table 3. 
Anginal attacks. The frequency of angina during the 
three phases of therapy, propranolol plus placebo (baseline 
phase), propranolol plus isosorbide dinitrate (adjunctive iso•
sorb ide) and propranolol plus nifedipine (adjunctive nifed•
ipine) is depicted in Figure I. Both adjunctive isosorbide 
(p < 0.001) and adjunctive nifedipine (p < 0.001) resulted 
Table 2. Staging Program for Graded Treadmill Exercise 
Testing for All 27 Patients Throughout the Study 
Stage Speed (mph) Grade (%) Time (min) 
2.0 3 3 
II 3.3 6 3 
III 3.3 9 3 
IV 3.3 12 3 
V 3.3 15 3 
VI 3.3 18 3 
VII 3.3 21 3 
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Table 3. Individual Patient Data: Anginal Attacks, Nitroglycerin Consumption, Total 
Exercise Duration 
Anginal Attacks Nitroglycerin Tablet Total Exercise Duration 
(per week) Consumption (per week) (seconds) 
Case B N B N B N 
4.0 5.0 3.0 3.0 5.0 2.3 360 345 495 
2 5.0 2.7 1.0 5.0 2.7 1.0 405 440 360 
3 5.5 6.3 3.0 5.5 5.0 2.7 240 300 375 
4 5.0 1.0 0 5.5 1.0 0 IXO 200 255 
5 6.5 3.3 3.5 0 0 0 420 420 540 
6 10.5 15.0 6.1 19.5 37.0 14.4 2X5 240 360 
7 5.5 2.2 2.0 5.5 2.0 1.0 255 360 420 
9 7.5 4.0 2.3 3.5 07 0.3 300 450 420 
10 5.5 1.3 0.7 HI 1.0 0.3 240 330 325 
II 60 12.2 5.7 4.0 X.X 2.0 IXO 180 210 
12 6.5 4.3 1.7 4.0 U U 360 540 540 
13 4.0 0 1.3 2.5 0 1.0 275 315 270 
15 9.7 7.0 1.0 5.9 5.7 1.0 300 360 720 
16 5.5 0 2.0 5.0 0 3.0 360 480 360 
17 5.1 6.3 5.9 4.2 03 1.3 315 420 555 
IX 7.5 4.3 5.3 7.5 4.3 5.3 360 330 390 
20 3.7 0 2.0 0 0 0 540 720 870 
21 5.5 1.8 1.1 5.0 1.8 1.1 2XO 345 390 
22 5.1 2.0 0 4.2 0.3 0 300 360 420 
23 5.8 2.5 3.7 58 2.5 3.7 465 540 600 
24 5.3 1.0 1.3 7.4 U 2.7 255 240 270 
25 13.5 1.7 1.3 7.0 0.7 1.0 480 540 500 
26 5.0 0 I) 2.0 0 0 300 570 630 
27 5.5 1.7 1.7 6.5 2.3 2.0 480 525 600 
28 5.5 0.7 03 0 0 0 540 720 780 
29 4.0 1.5 0.3 5.5 2.1 0.3 330 300 180 
30 4.0 3.7 3.3 3.5 3.7 2.7 465 540 540 
B = baseline; I = isosorbide dinitrate efficacy period; N = nifedipine efficacy period. 
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in a statistically significant reduction in angina frequency 
compared with propranolol alone. Adjunctive nifedipine was 
superior to adjunctive isosorbide in reducing the frequency 
of anginal episodes (p = 0.03). Nitroglycerin consumption 
was significantly reduced during adjunctive nifedipine ther•
apy compared with propranolol alone (p < 0.001), but not 
during adjunctive isosorbide therapy. Direct comparison of 
combination treatments did not result in statistically signif-
Figure 1. Frequency of anginal attacks and ni•
troglycerin consumption during the three phases 
of therapy. The frequency of anginal attacks showed 
a statistically significant decrease from baseline 
with both study medications. Adjunctive nifedi•
pine was superior to adjunctive isosorbide in re•
ducing angina; however, the difference was not 
statistically significant in terms of nitroglycerin 
consumption. Number of angina attacks = attacks 
per week. NTG consumption = number of nitro•
glycerin tablets taken per week. 
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Figure 2. Total exercise time and work load 
(METS) achieved for the three different treat•
ment groups. Patients exercised longer and to 
a greater work load than at baseline with both 
study medications, but nifedipine was more 
effective than isosorbide at a highly significant 
level. 
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icant differences, possibly because of the wide variability 
in nitroglycerin consumption that occurred during the ad•
junctive isosorbide phase. 
Exercise stress testing. Exercise performance of the three 
different treatment groups is summarized in Figures 2 and 
3. Total exercise duration, work load achieved at peak ex•
ercise, time to onset of angina and work load achieved at 
onset of angina were the variables selected for evaluation. 
Both combination therapies-adjunctive isosorbide and ad•
junctive nifedipine-were superior to propranolol alone in 
prolonging total exercise time. However, adjunctive nifed•
ipine resulted in a statistically significant increase in total 
exercise time when compared with adjunctive isosorbide 
dinitrate (p < 0.02). The work load achieved at end-exercise 
was significantly higher during both adjunctive treatment 
phases compared with propranolol alone (p = 0.001). The 
increase was higher during adjunctive nifedipine therapy 
than during adjunctive isosorbide dinitrate therapy (p < 
0.03). 
Of the 27 patients evaluated, 14 experienced angina dur•
ing both active drug treatment arms of the study (Fig. 3). 
Time to onset of angina was significantly prolonged during 
adjunctive nifedipine therapy compared with adjunctive iso•
sorb ide (p = 0.003) or propranolol therapy (p < 0.00l). 
In addition, the peak work load achieved at onset of pain 
was significantly higher during adjunctive nifedipine therapy 
as compared with either adjunctive isosorbide (p = 0.003) 
or propranolol (p < 0.001) therapy. 
Effect on rate-pressure product. The rate-pressure 
product (double product) at peak exercise and at submaximal 
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Figure 3. Comparison of 14 patients who ex•
perienceQ angina with treadmill testing during 
both efficacy periods. Both nifedipine and iso•
sorbide increased time to angina and METS 
achieved at onset of pain, but improvement was 
statistically greater with adjunctive nifedipine 
than with adjunctive isosorbide. 
JACC Vol. 6. No.6 
December 1985: 1395-40 I 
MORSE AND NESTO 
ADJUNCTIVE THERAPY AND EXERTIONAL ANGINA 
1399 
DOUBLE PRODUCT 
AT END OF EXERCISE 
N=27 
DOUBLE PRODUCT 
AT SUB MAXIMAL WORKLOAD 
(END OF STAGE I) 
Figure 4. Rate-pressure products (dou•
ble product of heart rate [beats per min•
ute] times systolic blood pressure [milli•
meters of mercury ]) attained at end-exercise 
in all three groups compared with those 
attained at end of stage I. 
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NS 
work load (end of stage I) was calculated for all three treat•
ment groups (Fig. 4). Because of a decrease in both heart 
rate and systolic blood pressure, the rate-pressure product 
at submaximal exercise was significantly lower during ad•
junctive nifedipine therapy than during adjunctive isosorbide 
dinitrate or propranolol therapy (Fig. 5). However, at the 
onset of angina in 14 patients, and at end-exercise in all 27 
patients, no statistically significant difference was observed 
between the rate-pressure product recorded during the pro•
pranolol baseline period and that recorded during either 
adjunctive treatment phase (Fig. 6). 
Although 27 patients experienced angina on treadmill 
testing when receiving propranolol alone, 13 patients had a 
fatigue-limited exercise test during one or both adjunctive 
treatment periods. Ten patients were pain-free during ad•
junctive nifedipine administration and six patients during 
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adjunctive isosorbide administration. The rate-pressure 
products achieved at end-exercise by these patients were 
not significantly different from those achieved by the 14 
patients with a symptom-limited exercise test during ad•
junctive therapy or from those achieved by all patients dur•
ing the propranolol baseline phase. 
Adverse effects. During both adjunctive treatment phases, 
approximately one-half of the patients reported side effects 
judged to be mild to moderate, although three patients re•
quired premature crossover from isosorbide to nifedipine 
ajunctive therapy because of intolerable headache experi•
enced with isosorbide. Side effects were encountered at a 
similar frequency during both adjunctive phases and con•
sisted primarily of headache during the isosorbide adjunctive 
phase and lightheadedness, pedal edema and gastrointestinal 
upset during the adjunctive nifedipine phase. However, pa-
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Figure 5. Components of the rate-pressure product 
(double product) at submaximal work load. At the end 
of stage I, there was a highly significant difference in 
both blood pressure and heart rate when patients were 
taking adjunctive nifedipine compared with adjunctive 
isosorbide or propranolol alone. 
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Figure 6. Rate-pressure products (double 
product) of 14 patients experiencing pain 
during both active treatment phases of the 
study compared with the rate-pressure prod•
ucts of all 27 patients at end exercise. 
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tients whose dose of isosorbide could be titrated beyond the 
initial dose appeared to have fewer long-term side effects 
than those patients receiving adjunctive nifedipine. 
Discussion 
Clinical relevance. At present, three classes of phar•
macologic agents provide realistic therapeutic alternatives 
for physicians treating patients with angina pectoris. Interest 
in defiI1ing optimal medical treatment for angina is rising 
given the recent findings of the Coronary Artery Surgery 
Study (CASS) demonstrating equivalent survival rates after 
medical and surgery therapy in certain symptomatic patients 
with coronary artery disease (9). Beta-adrenergic blocking 
agents and long-acting nitrates either alone or in combi•
nation reduce the frequency of angina and improve the qual•
ity of life in many symptomatic patients. The introduction 
of calcium channel blockers now adds an additional ther•
apeutic alternative to long-acting nitrates as combination 
treatment with beta-blocker medication. The present study 
was conceived to examine the commonly encountered clin•
ical question of which agent or agents to add when patients 
remain symptomatic despite maximally tolerated doses of a 
beta-blocker. 
Nifedipine effectively reduces angina when used as a 
single agent (10,11), and several studies (3-8,12) have in•
dicated that it is a safe and beneficial agent when used 
adjunctively with a beta-blocker. Except for the recent study 
by Tolins et al. (8), there are no data that systematically 
compare the combihation ofnifedipine and propranolol with 
the most common form of antianginal combination treat•
ment: propranolol and isosorbide dinitrate. The current in•
vestigation differs from the work of Tolins et al. in that the 
antianginal effects of either nifedipine or isosorbide dini•
trate, administered adjunctively with propranolol, were 
measured after careful dose titration to tolerance followed 
by maintenance of each agent for a period of 3 weeks, as 
compared with examining therapeutic effects of adjunctive 
administration after an acute single dose. 
Therapeutic benefits. This was a randomized double•
blind crossover investigation utilizing a study group that 
remained symptomatic despite adequate beta-blockade. Study 
medications were titrated individually to tolerance. A de•
tailed analysis of the data obtained during chronic coad•
ministration of each study medication plus propranolol was 
performed using patient diaries of anginal episodes and ni•
troglycerin tablet counts to assess clinical efficacy. Clearly 
both combination therapies proved superior to propranolol 
alone in reducing the frequency of anginal attacks. How•
ever, an additional statistically significant reduction could 
be demonstrated when adjunctive nifedipine therapy was 
compared with adjunctive isosorbide dinitrate therapy. Fur•
thermore, only with adjunctive nifedipine therapy was there 
a significant reduction in nitroglycerin consumption com•
pared with the baseline period when patients were taking 
propranolol alone. 
A second goal of management of angina is the attempt 
to improve patient life-style by improving exercise perform•
ance with drug therapy. Several variables of exercise per•
formance were measured during this study including total 
exercise time, time to onset of angina, work load achieved 
at end of exercise and work load achieved at onset of angina. 
Although both adjunctive therapies improved exercise per•
formance when compared with propranolol alone, the im•
provement observed was significantly greater during ad•
junctive nifedipine therapy than during adjunctive isosorbide 
dinitrate therapy. This improvement was seen in all four 
patient response categories and the differences were highly 
significant. 
Mechanism of action. To reduce myocardial ischemia, 
any antianginal agent, whether used alone or in combina•
tion, must favorably affect the balance between myocardial 
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oxygen supply and demand. In our study, adjunctive nifed•
ipine therapy was more effective than adjunctive isosorbide 
dinitrate therapy in reducing the rate-pressure product at 
submaximal exercise (Fig. 5), a mechanism that may ac•
count for the ability of the nifedipine-propranolol combi•
nation to prolong exercise time. Because systolic blood pres•
sure is an important determinant of left ventricular wall 
tension and myocardial oxygen consumption during exer•
tion, it is conceivable that afterload (affected by nifedipine) 
is more important than preload (affected by nitrates) as a 
determinant of myocardial oxygen demand during exercise 
when diastolic filling time is substantially shortened, Fur•
thermore, the reflex increase in heart rate, frequently cited 
as a negative aspect of either nifedipine or nitrate mono•
therapy, was abolished during coadministration with 
propranolol. 
In addition to the beneficial effect of nifedipine on the 
peripheral circulation, other mechanisms may explain this 
agent's efficacy when used adjunctively with propranolol. 
Numerous studies (13) have suggested that nifedipine en•
hances coronary blood flow, with concomitant beneficial 
effects on angina threshold and maximal exercise capacity. 
Malacoff et al. (14) observed that nifedipine improved myo•
cardial blood flow in regions of myocardium subserved by 
coronary artery segments with significant stenoses. In ad•
dition, Engel and Lichtlen (15) noted improved coronary 
blood flow in poststenotic regions when nifedipine was ad•
ministered during atrial pacing compared with the results 
obtained when propranolol and nitroglycerin were admin•
istered, The recent observation that propranolol may ac•
tually potentiate coronary vasoconstriction when patients are 
challenged with cold pressor testing (16) provides another 
possible explanation for the observed efficacy of nifedipine 
since this agent may exert a selective antivasoconstrictor 
effect on the coronary vasculature (7). 
Although the rate-pressure products observed at end-ex•
ercise after the addition of either nifedipine or isosorbide 
dinitrate were not significantly different from propranolol 
baseline values, 13 of 27 patients discontinued exercise 
because of fatigue rather than angina. The fact that these 
patients (who were predominantly, but not exclusively, in 
the nifedipine group) were limited by fatigue rather than 
pain at comparable rate-pressure products suggests that an 
increase in myocardial blood flow may be a factor in im•
proving exercise capacity in this particular cohort of patients. 
Conclusions. This study demonstrated that adjunctive 
administration of nifedipine or isosorbide dinitrate with pro•
pranolol is more effective than propranolol alone in reducing 
symptomatic angina pectoris, The combination of nifedipine 
and propranolol appears to be significantly more effective 
than the combination of isosorbide dinitrate and propranolol 
in reducing angina and improving exercise performance dur-
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ing standardized exercise tolerance tests. Side effects were 
encountered at a similar frequency during both combination 
therapies. 
We thank lean Cappelen for the excellent nursing assistance she provided 
during this study. 
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